Opinion|Videos|August 29, 2024
When CML Therapy Shifts: Collaborative Approaches to Treatment Changes
Claire Saxton shares insights on how physicians and caregivers can best assist patients with CML who have switched therapies.
Advertisement
Episodes in this series
This program was made possible with support from Novartis Pharmaceuticals.
Video content above is prompted by the following questions:
- In your experience, how can physicians and caregivers both support patients in navigating a therapy change? Which resources can best help support patients during a treatment transition?
Advertisement
Related to this article
The approval expands the indication of pirtobrutinib to patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma with no known 17p deletion.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer
2
FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer
3
Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma
4
Considering Talquetamab and Emerging Bispecifics in R/R Multiple Myeloma
5